3.2. Levels of MCL-1 and Its Endogenous Inhibitors, BIM and NOXA, Are Modulated in Trametinib-Resistant Melanoma Cells during Alternating Periods of Trametinib Withdrawal and Rechallenge. This evidence concerns the gene BCL2L11 and melanoma.